

## References

- Albert, M.A.; Danielson, E.; Rifai, N. and Ridker, P.M. (2001). Effect of statin therapy on C-reactive protein levels: the prava-statin inflammation/ CRP evaluation (PRINCE): A randomized trial and cohort study. JAMA. 286(1): 64-70.
- Al-Jada, A.; Gray, R.; Ghanim, H.; Mohanty, P.; Hamouda, W.; et al. (2001). Nuclear factor Kappa B stimulatory effects of troglitazone in obese patients with type 2 diabetes: Evidence of an anti-inflammatory action?. J.Clin.Endocrinol. Metab. 86(7): 3250-6.
- Anonaymous , ( 2004 ) . Women's high CRP Levels can predict hypertension . lthealthcare Benchmarks – Qual – Improv . 11 ( 2 ) : 20-1 .
- Barinas-Michell, E.; Cushman, M.; Meilahn, E.; Tracy, R. and Kuller, L. (2001). Serum levels of C-reactive protein are associated with obesity, weight gain, and hormone replacement therapy in healthy post menopausal women. Am.J.Epidemiol. 153: 1094-100.
- Bello, N. and Mosca, L. ( 2004). Women's high CRP levels can predict hypertension. Prog.Cardiovasc.Dis. 46(4): 287-95.
- Blumberg, B.; Gerstley, B.; Hungerford, D.; London, W. and Sutnick, A. (1967). A serum antigen(Australia antigen) in Down's syndrome, leukemia and hepatitis. Ann.Intern.Med. 66:924-31.
- Blumberg, B.; Krugman, S.; Moderator, S. (1982). Passive and active immunization and treatment. In: Szmunes, W.; Alter, H. J. and Maynard, J. Viral hepatitis- 1981 international symposium. Philadelphia-Franklin Institute Press.
- Boon, N.A.; Fox, K.A.; Bloomfield, Pand Bradbury, A. (2002). Clardiovascular disease. In: Haslett, C.; Chilvers, E.; Boon, N.; Colledge, N. and Hunter, J. Davidicine. 19<sup>th</sup> Ed. Churchill Living-Stone. Pp: 450-453.

- Braunwald, E.; Fanci, A. ; Kaspar, D.; Hanser, S.; Longo, D.; et al., (2001). Harrison's principles of internal medicine. 15<sup>th</sup> Ed. Mc Graw-Hill, Medical publishing division.
- Burtis. C.A. and Ashwood, E.R. (1999). Tietz test book of clinical chemistry. Vol. 2. 3<sup>rd</sup>. Ed. Saunders company USA.. P: 493.
- Cary,M.C. and Robins, S. (1994). Bilirubin production and secretion. In: Stein, J.; Hutton,J.; O'Ronk, R.; Samuels, M.;Triet, S.; et al. Internal Medicine. 4<sup>th</sup>.Ed. Mosby-Year Book, Inc.
- Cermak, J.; Key, N.S.; Bach, R.R. (1993). C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood, 82: 513-520.
- Chambers, J.C.; Eda, SH.; Bassett,P.; Karim, Y.; Thompson S.; et al. (2001). C-reactive protein, insulin resistance, central obesity and coronary heart disease risk in Indian Asian from the United Kingdom compared with European whites. Circulation, 104: 145-50.
- Chan, D.C.; Watts, G.; Barrett, H.; Beilin, L. and Mori T. (2002). Effect of Atorvastatin and fish oil on plasma high sensitivity C-reactive protein concentrations in individuals with visceral obesity. Clin.Chem. 48(6): 877-83.
- Chau, K.H.; Hargie., M.P.; Decker, R.H.; Mushahwar, I.K.; Overby, L.R. (1983). Serodiagnosis of recent hepatitis B infection by IgM class anti-HBc. Hepatology, 3: 142-149.
- Chew, D.P.; Bhatt, D.; Robbins, M.; Penn, M.; Schneider J.; Lauer,M; et al. (2001). Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation, 104: 992.7.
- Corrall, C.J.; Pepple, J.; Moxon, E. and Hughes, W. (1981). C-reactive protein in spinal fluid of children with meningitis.J.Pediatr. 99:365-9.

- Curb,J.D.; Abbott, R.; Rodjiguez,B.; Sakkinen, P.; Popper, J.; et al. (2003). C-reactive protein and the future risk of thromboembolic stroke in healthy men. *Circulation*, 107: 2016-20.
- Cushman,M.; Legault, C.; Barrett-Conner, E.; et al.,(1999). Effect of Postmenopausal hormones on inflammation sensitive protein: The Postmenopausal Estrogen/ Progestin Intervention (PEPI) study. *Circulation* 100: 717-22.
- Danesh, J.; Muir, J.; Wong, Y.; et al., (1999). Risk factors for coronary heart disease and acute phase proteins, a population- based study. *Eur.Heart. J.* 20: 945-59.
- Dasgupta A.(1992). *Modern Immunology, basic, clinical laboratory*. 2<sup>nd</sup>.Ed. Jaypee brothers.
- Daw, M.A.; Siala, I.; Warfalli, M. and Muflah, M. (2000). Seroepidemiology of hepatitis B virus markers among certain potential risk factors. *Saudi Med. J.* 21(12): 1157-60.
- DemirdagK.; Ozden,M.; Kalkan, A.; Godekmerdan, A. and Sirri-Kilic, S., (2003). Serum cytokine levels in patients with acute brucellosis and their relation to the traditional inflammatory markers. *FEMS.Immuno. Med. Microbiol.* 39(2): 149-153.
- Desmet,V.J.; Gerber, M.; Hoofnagle, J.; et al. (1994). Classification of chronic hepatitis. Diagnosis, grading and staging. *Hepatology*. 19:1513-20.
- Devaraj, S.;Yan,X. u, D. and Jialal, I. (2003). C-reactive protein increases plasminogen activation inhibitor-1 expression and activity in human aortic endothelial cell. *Circulation*, 107:398-404.
- deWinter, R.; Fischer, J.; Bholasingh,R.;vanStraalen, J.; Jong, T.; et al. (2000). C-reactive protein and cardiac Troponin T in risk stratification: Differences in optimal timing of tests early after the onset of chest pain. *Clin.Chem.* 46(10): 1597-1603.

- Dibra, A.; Mechilli, J.; Braun, S.; Hadamitzky, M.; Braun, H.; Dirchinger J. et al. (2003). Association between C-reactive protein levels and subsequent cardiac events among patients with stable angina treated with coronary artery stenting. *Am.J.Med.* 114: 715-22.
- Dienstage J.L. and Isselbacher, K.J. (1998). Acute viral hepatitis. In: Fauci, A.; Braunwald, Em; Isselbacher, K.; Wilson J.; Martin,J. et al. *Harrison's Principles of internal Medicine*. 14<sup>th</sup>. Ed. McGraw-Hill, Pp: 1677-89.
- Dienstage,J.L.; and Isselbacher,K. (2001). Acute viral hepatitis. In: Braunwald, E.; Fauci, A.; Kasper, D.; Hauser, S.; Longo, D. and Jameson, J. *Harrison's Principles of Internal Medicine*. 15 th. Ed. McGraw-Hill. Pp: 1721.
- Di-Naro , E .; Ghezzi, F. ; Raio , L . ; Ramano, F.; Mueller,M.; et al . (2003 ) . C-reactive protein in vaginal fluid of membranes. *Acta. Obstet. Gynecol.Scand.* 82(12): 1072-79.
- Doumas, B.T.; Bayse, D.D.; et al. (1981). A candidate reference method for determination of total protein in serum. I. Development and validation. II. Test for transferability. *Clin. Chem.* 27: 1642-54.
- Doumas, B.M. and Wu, T.W. (1991). The measurement of bilirubin fractions in serum. *CRC. Crit. Rev. Clin. Lab. Sci.* 28: 415-46.
- Dufour, D.R. (2001). Evaluation of liver function and Injury. In: Henry, J.B. *clinical Diagnosis and management by laboratory method*. 20<sup>th</sup> Ed. W.B. Saunders company. Pp: 264-278
- Fathalla, S.; Al-Jama, A.; Al-Sheikh, I.; El-Rifaei, A.; Younis, Y.; et al. (1998). Seroepidemiological prevalence of hepatitis B virus markers in Eastern Saudi Arabia. *Saudi Med. J.* 19(3): 283-88.
- Feldmann, G. (1982). Synthesis and secretion of acute phase proteins by the hepatocytes from rats with normal liver or cirrhosis during the inflammatory reaction. *Ann. N.Y. Acad. Sci.* 389: 446-7.
- Fiore, M.; Mitehell, J.; Doan, T.; Nelson, R.; Winter, G.; Grandon,C. et al. (1988). The Abbott IM<sub>x</sub><sup>tm</sup> Auto mated Benchtop immuno analyzer system. *Clin.Chem.* 34: 1726-32.

- Ford, E.S. (2002) . Does exercise reduce inflammation?. Physical activity and C-reactive protein among U.S. adults. *Epidemiology*, 13: 561-568.
- Ford, E.S.; Giles, W.; Myers, G. and Mannino, D. (2003 a). Population distribution of high-sensitivity C-reactive protein among US men: Findings from National Health and Nutrition examination survey, 1999-2000. *Clin. Chem.* 49(4): 686-89.
- Ford, E.S.; Giles, W.; Myers, G.; Rifai, N.; Ridker, P. and Mannino, D. (2003b). C-reactive protein concentration distribution among US children and young adults: Findings from the National Health and Nutrition examination survey. 1999-2000. *Clin. Chem.* 49(8): 1353-57.
- Franco, A.; Guidotti, L.; Hobbs, M.; et al.(1997). Pathogenic effector function of CD<sub>4</sub> positive T helper 1 cells in hepatitis B virus transgenic mice. *J.Immunol.*159: 2001-8.
- Freeman, D.J.; Norrie, J.; Caslake, M.J.; et al (2002). C-reactive protein is an independent predictor of risk for the development of diabetes in the west of Scotland coronary prevention study. *Diabetes*, 51: 1596-600.
- Frohlich M.; Doring, A.; Imhof, A.; Hutchinson, W.; Pepys, M.; Koenig, W.; et al. (1999). Oral contraceptive use is associated with a systemic acute phase response. *Fibrinolysis and Proleolysis*, 13: 239-244.
- Frohlich , M . ; Imhof , A . ; Berg , G . ; et al . , ( 2000 ) . Association between C- reactive protein and features of metabolic syndrome : a population – based study . *Diabetes Care* , 23 : 1835 – 1839 .
- Gambino, R.( 1997). C-reactive protein under valued, under utilized. *Clin.Chem.* 43(11): 2017-18.
- Ganem, D. and Schneider, R. (2001). *Hepadnaviridae* and their replication. In: Knipe, D.; Howley P.; Chanock, R.; Monath, T.; Roizman, B. and Straus, S. Field's Virology. 4<sup>th</sup>.Ed. Philadelphia: Lippincott-Raven. PP 2703-36.
- Gewurz,H.; Zhang, X. and Lint, T. (1995). Structure and function of pentraxin. *Curr.Opin. Immunol.* 7: 54-64.

- Glantz, S.A. (1987). Primer of Biostatistics. 2nd . Ed. New Yourk. Mc Graw-Hill, Pp: 287-330.
- Golds, R.A.; Kindt, T. and Osborne,B.(2000). Kuby Immunology.4<sup>th</sup>.Ed. PP: 384-86.
- Gould, J.M. and Weiser, J.N. (2001). Expression of C-reactive protin in human respiratory tract. Infect.Immunol. 69(3): 1747-54.
- Greenfield,J.R.; Samaras, K.; Jenkins, A.; Kelly, P.; Spector, T.;et al. (2004). Obesity is an important determinant of baseline serum C-reactive protein concentration in monozygotic twins, independent of genetic influences. Circulation, 109(22): 3022-28.
- Hardin, G.A.( 2000). Use of laboratory test in rheumatology and clinical Immunology. In: Humes H.D.; Dupont, H.;Gardner, L.; et al. Killey's TextBook of Internal Medicine. 4<sup>th</sup>. Ed. Lippincott-Walliams & Wilkans, USA.
- Harrison, T.J.; Dusheiko,G. and Zuckerman, A. (2000). Hepatitis viruses. In: Zuckerman, A.; Banatvala, J.; Pattison, J. Principles and practice of clinical virology. 4<sup>th</sup>.Ed. John Wiley & Sons, LTD. PP 187-218.
- Hashimoto,H.; Kitagawa, K.; Hougaku, H.; Shimizu, Y.; Sakagucki, Y.;et al. (2001). C-reactive protein is an independent predictor of the rate of increase in early carotid atherosclerosis. Circulation, 104(1): 63-67.
- Haslett, C.; Chilvers, E.; Boon, N.; et al. (2002). Davidsn's Principles and Practice of Medicine. 19<sup>th</sup>. Ed. Churchill Livingstone.
- Hassan, A. (2004). Outbreak of hepatitis B virus infection in rural community in Diyala. Journal of Diyala, 18: 45-52.
- Hayes,P.; Simpson, K. and Garden, O. (2002). Liver and biliary tract disease.In: Haslett,C.; Chilvers, E.; Boon, N.; Colledge, N.; Hunter,H. Davidson's Principle and Practice of Medicine. 19<sup>th</sup>. Ed. Churchil Livingstone, PP. 831-61.
- Hegel, R.A.; Ban, M. and Young, T.(2001). Serum C-reactive protein in Canadian I unit and it's association with genetic variation on chromosome 1q21. Clin.Chem. 47: 1707- 09.

- Heijtkink, R.; Paulij, W.; vanRoosmalen, M.; Hellinger, J.; Neisters, H.; et al. (1999). Characterization of the early phase of chronicity in acute hepatitis B infection. *J.Med. Virol.* 57: 331-6.
- Hiura,M.; Kikuchi T.; Nagasaki, K. and Uchiyama, M. (2003). Elevated of serum C-reactive protein levels is associated with obesity in boys. *Hypertens. Res.* 26(7): 541-46.
- Hollinger, F.B. (1996). Hepatitis B virus. In: Fields, B.N.; Knipe, D.M. and Howley, P.M. *Fields Virology*. Vol.2. 3<sup>rd</sup>.Ed. Lippencott-Raven. Publishers PP 2739-807.
- Hollinger, F.B. and Dienstag, G. (1999). Hepatitis B and D viruses In: Murray, P.R. *Manual of Clinical Microbiology*. Vol.2. 7<sup>th</sup>.Ed. American Society for Microbiology. PP 1025-42.
- Huang, S.; Tang,R.;Chen.S. and Chung, R. (2003). Serum interleukin-6 level as a diagnostic test in children with sepsis. *J.Clin.Med. Assoc.* 66(9): 523-27.
- Hutchison, W.L.; Koenig, W.; Frohlich,M.; Sund,M.; Lowe, G.; Pepys, M.B. (2000). Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. *Clin. Chem.* 46(7): 934-38.
- Imhof, A.; Froehilch, M.; Brenner, H. ; et al. (2001). Effect of alcohol consumption on systemic markers of inflammation. *Lancet*, 357: 763-7.
- Ishibashi,M.; Takemura,Y.; Ishid, H.; Watanabe, K. and Kawai T. (2002). C-reactive protein kinitics in newborns: Application of high-sensitivity analytic method in its determination. *Clin.Chem.* 48(7):1103-6.
- Janeway, C.A.; Travers, P. and Walport,M. (1999). *Immunology, the immune system in health and disease*. 4<sup>th</sup>. Ed.J. Donald Corpa. PP 384-85.
- Jang,T.N.; Yeh, D.; Shen, S.; Huang, C.; Jiang, J. and Kao, S. (2004). Severe acute respiratory syndrome in Taiwan: Analysis of epidemiological characteristics in 29 cases. *J.Infect.* 48(1): 23-31.

- Johnson, R.D.; O'Connor, M.L.; Kerr, R.M. (1995). Extreme serum deviations of aspartate aminotransferase. *Am. J. Gastroenterol*, 90: 1244-5.
- Jones, A.M.; Martin, L.; Bright-Thomas, R.; Dodd, M.; McDowell, A.; et al. (2003). Inflammatory markers in cystic fibrosis patients with transmissible *Pseudomonas aeruginosa*. *Europ. Respir. J.* 22(3): 503-6.
- Juszczyk, J. (2000). Clinical course and consequences of hepatitis B infection. *Vaccine*, 18: s23 – s25.
- Kane, M.A. (1996). Global status of hepatitis B immunization. *Lancet*, 348: 696.
- Kaplan, M.H. (1982). C-reactive protein: Relation to disease and pathological significant. *Ann. N.Y. Acad. Sci.* 89: 419-22.
- Kawai, H. and Feinstone S. (2000). Acute viral hepatitis. In: Mandell, G.; Bennett, J. and Dolin, R. *Principles and Practice of infectious disease*. Vol.1. 5<sup>th</sup>. Ed. Churchill-Livingstone, USA PP: 860-65.
- Keeffe, E.B. (2003). Acute/chronic viral hepatitis. In: Dale, D. and Federman, D. *Web.MD. Scientific American Medicine*. Vol. 1. Web. MD. INC. USA. PP 810-28.
- Kessler, N.; Cyteval, C.; Gallix, B.; Lesnik, A.; Blayac, P. et al. (2004). Appendicitis of sensitivity, specificity and predictive value of US, Doppler and laboratory findings. *Radiology*, 230(2): 472-8.
- Khuseyinova, N.; Imhof, A.; Trischler, G. Rothenbacher, D.; Hutchison, W.; et al. (2003). Determination of C-reactive protein: Comparison of three high sensitivity immunoassay. *Clin. Chem.* 49: 1691-95.
- Kindmark, C.O. (1972). The concentration of c-reactive protein in sera from healthy individuals. *Scan. J. Clin. Lab. Invest.* 29: 407-411.
- Koc, M.; Taysi, S.; Sezen, O. and Baken, N. (2003). Levels of some acute phase protein in the serum of patients with cancer during radiotherapy. *Bio. Pharm. Bull.* 26(10): 1494-97.
- Koenig, W. (2001). C-reactive protein and cardiovascular risk: Has the time come for screening the general population. *Clin. Chem.* 47(1): 9-10.



- Koenig, W.; Lowel, H.; Baumert, J. and Meisinger, C. (2004). C-reactive protein modulates risk prediction based on the Framingham score implications for future risk assessment: Results from a large cohort study in Southern Germany. *Circulation*, 109: 1349-53.
- Koukkun, H.; Penttilä, K.; Kempainen, A.; Halinen, M.; Penttilä, I.; et al. (2001). C-reactive protein, fibrinogen, interleukin-6 and tumor necrosis factor- $\alpha$  in the prognostic classification of unstable angina pectoris. *Ann. Med.* 33(1): 37-47.
- Koziel, M. (1996). Immunology of viral hepatitis. *Am. J. Med.* 100: 98-109.
- Liu, L.; Zhao, S.H.; Cheng, V and Li, Y. (2003). Xuezhikang decreases serum lipoprotein (a) and C-reactive protein concentration in patients with coronary heart disease. *Clin. Chem.* 49: 1347-52.
- Liuzzo, G.; Biasucci, L.; Gallimore, J.; Grill, R.; Buzzi, A.; et al. (1994). The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. *N. Engl. J. Med.* 331: 417-24.
- Loab, S.; Hamilton, H. (1991). Clinical Laboratory tests: values and implications. Springhouse corporation. Pennsylvania USA.
- Loab, S.; Cahill, M.; Hubbard, J.; DaCunha, J.P.; Lewis, J.; et al. (1993). Illustrated guide to diagnostic tests. Springhouse corporation, Pennsylvania. USA. Pp: 100-225.
- Lok, A.; Heathcote, E. and Hoofnagle, J. (2001). Management of hepatitis B: Summary of workshop. *Gastroenterology*, 120(7): 1828-53.
- Macintyre, S.; Schultz, Z. and Kushner, I. (1982). Biosynthesis of C-reactive protein. *Ann. N.Y. Acad. Sci.* 389: 76-87.
- Macy, E.; Hayes, T. and Tracy, R. (1997). Variability in the measurement of C-reactive protein in healthy subjects: implication for reference intervals and epidemiological application. *Clin. Chem.* 43:52-58.
- Manian, F.A. (1995). A prospective study of daily measurement of C-reactive protein in serum of adults with neutropenia. *Clin. Infect. Dis.* 21:114-21.

- Mansa, V.; Castro, K.; Matos, S.; Junqueira, N.; Souza, S.; et al. (2003). Compliance with hepatitis B virus vaccination and risk of occupational exposure to blood and other body fluids in intensive care department personnel in Brazil. *Am.J.Infect. Control*, 31:431-34.
- Matesanz J.L.; Fernandez, E.; Fernandez, J. and Viejo, G.(2003). Plasma procalcitonin and C-reactive protein concentrations in pediatric patients with Epstein-Barr virus infection. *Clin.Chemist.* 49(12): 2103-4.
- Maynard, J.E. (1990). Global importance and need for control. *Vaccine*, 8:18-20.
- McCarty, M. ( 1982). Historical perspective on C-reactive protein *Ann.N.Y. Acad. Sci.* 389:1-9.
- McLaughlin, T.; Abbasi, F.; Lamendola, C.; et al. (2002). Differentiation between obesity and Insulin resistance in the association with C-reactive protein. *Circulation*, 106:2908-12.
- Meheus , A. ( 1995 ) . Risk of he patitis in adolescence and young adulthood . *Vaccine* , 13 ( 1 ) : S 31 – S 34 .
- Mimms, L.; Moseley, J.; Hollinger, F.; Aach, R.; Stevens, C.; et al.(1993). Effect of concurrent acute infection with hepatitis C virus on acute hepatitis B virus infection. *Br.Med. J.* 307: 1095-97.
- Mold, C.; Gewuza, H. and DuClos, J.(1999). Regulation of complement activation by C-reactive protein. *Immunopharmacology*, 42: 23-30.
- Mondell, M.; Mieli-Vergani G.; Alberti, A. et al. (1982). Specificity of T lymphocyte. *J.Immunol.* 129:2773.
- Mortensen, R.F. (2001). C-reactive protein, inflammation and innate immunity. *Immunol. Res.* 24: 163-176.
- Moss, D. and Henderson, A. (1999). Clinical enzymology. In: Burtis, C. and Ashwood, E. Tiezts Textbook of Clinical chemistry. Vol. 2. 3<sup>rd</sup>.Ed. W.B. Saunders company. PP: 651-58.
- Nagafuchi, Y. and Scheuer, P. (1986). Expression of B<sub>2</sub>-microglobulin on hepatocytes in acute and chronic type B hepatitis. *Hepatology*, 6:20-23.

- O'Grady, J.; Alexander, G.; Hayllar, K. and Williams, R. (1989). Early indicators of prognosis in fulfulminernt hepatic failure. *Gastroenterology*, 97: 439-445.
- Painter, P.; Cope, J.; Smith, J. (1999). Reference information for clinical laboratory. In: Burtis, C and Ashwood, E. Tietz's text book of clinical chemistry. Vol. 3. 3<sup>rd</sup> Ed. W.B. Saunders company. P: 1799-1831.
- Parkin, J. and Cohen, B. (2001). An overview of the immune system. *Lancet*, 357:1777-89.
- Pasceri, V.; Chang, J.; Willerson, J. and Yeh, E. (2001). Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. *Circulation*. 103: 2531-34.
- Peltomaa, R.; Paimela, L.; Helve, T. and Leirisalo-Repo, M. (2001). Effect of treatment on outcome of very early rheumatoid arthritis. *Scand. J. Rheumatol.* 30 (3): 143-48.
- Penna, A.; Artini, M.; Cavall, A.; Levrero, M.; Bertolotti, A.; et al. (1996). Long-lasting memory T cell responses following self-limited acute hepatitis B. *J. Clin. Invest.* 98: 1185-94.
- Pepys, M.B. (1998). C-reactive protein. In: Delves, P. and Roitt, M. *Encyclopedia of immunology*. Vol. 2, 2<sup>nd</sup>. Ed. Academic press. PP 663-65.
- Pepys, M.B. and Baltz, M. (1983). Acute phase proteins with special reference to C-reactive protein and related proteins (Pentraxin) and serum amyloid A protein. *Adv. Immunol.* 34:141-212.
- Pepys, M.B. and Hirschfield, C. (2003). C-reactive protein: A critical update. *J. Clin. Invest.* 111(12): 1805-12.
- Pepys, M.B.; Rowe, L. and Baltz, M. (1985). C-reactive protein: binding to lipids and lipoproteins. *Int. Rev. Exp. Pathol.* 27:83-111.
- Peutherer, J.F. (1997). Hepadnaviruses. In: Greenwood, D.; Slack, R. and Peutherer, J. *Medical Microbiology*. 5<sup>th</sup>. Ed. Churchill Livingstone. PP 439-447.

- Pignatalli, M.; Waters, J.; Brown, D.; et al. (1987). Cytotoxic T cell responses to the nucleocapsid proteins of HBV in chronic hepatitis. Evidence that antibody modulation may cause protracted infection. *J.Hepatol.* 4:15-21.
- Plenge, J.; Hernandez, J.; Weil, K.; Poirier, P.; Grunwald, G.; et al. (2002). Simvastatin lowers C-reactive protein within 14 days, an effect independent of low density lipoprotein cholesterol reduction. *Circulation*, 106: 1447-52.
- Podolsky, D.K. (1998). Derangements of hepatic metabolism in: Fauci, A.S.; Braunwald, E.; Isselbacher, K.; Wilson, J. ; Martin, J. ; et al. 14<sup>th</sup> Ed. McGraw-Hill, health professions division.
- Pradhan, A.; Manso, J. Rifai, N. ; et al. (2001). C-reactive protein, interleukin-6, and of developing type 2 diabetes mellitus. *JAMA*. 286: 327-34.
- Pratt, D. S. and Kaplan, M.M. (2001). Evaluation of liver function. In: Brounwald, G.; Fanci, A.S. ; Kasper, P.L. ; Hauser, S. , Longo, D. and Jameson, J.L. 15<sup>th</sup> Ed. Mc-GawHill, Medical publishing division. Pp: 1712.
- Rajs, G.; Finzi, Z.; Rajs,A. and Mayers, M.(2002). C-reactive protein concentration in cerebral spinal fluid in gram-positive and gram-negative bacterial meningitis. *Clin. Chem.* 48(3): 541- 595.
- Rehermann, B.; Lau, D.; Hoofnagle J.and Chisari, F. (1996). Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. *J. Clin. Invest.* 97(7): 1655-65.
- Requejo, H. and Cocaza, A. (2003). C-reactive protein in the diagnosis of community acquired pneumonia. *Braz.J Infect. Dis.* 7(4): 241-244.
- Ridker, P.; Rifai,N.; Clearfield,M.; Downs, J.; Weise, S.; Miles, J. and Gotto, A. (2001(a)). Measurement of C-reactive protein for the targeting of Statin therapy in the primary prevention of acute coronary events. *N.Engl. J.Med.* 344: 1959-65.
- Ridker, P.M.; Hennekens, C.; Buring, J. and Rifai N.(2000). C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. *N.Engl. J.Med.* 342: 836-43.
- Ridker, P.M.; Hennekens, C.; Rafai, N. and Manson, J.(1999). Hormone replacement therapy and increased plasma concentration of C-reactive protein. *Circulation*, 100: 713- 716.

- Ridker, P.M.; Wilson, P. and Grundy S. (2004). Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk ?. *Circulation*, 109:2818- 25.
- Ridker, P.M.;Buring, J.; Cook, N. and Rafai, N. (2003). C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: An8-years follow-up of 14791 initially healthy American women. *Circulation*, 107: 391-97.
- Ridker, P.M.;Rifai,N. and Lowenthal, S. (2001(b)). Rapid reduction in C-reactive protein with cerivastation among 785 patients with primary hypercholestrolemia. *Circulation*, 103: 1191-1193.
- Ridwelski, K.; Meyer, F.; Ebert, M.; et al.(2001). Prognostic parameters determining survival in pancreatic carcinoma and in particular after palliative treatment. *Dig.Dis.* 19(1): 85-92.
- Roberts, W.L.; Moulton, L.; Law, T.; Farrow, G.; Cooper, M.;et al. (2001). Evaluation of nine automated high sensitivity C-reactive protein methods: Implications for clinical and epidemiological applications (Part 2). *Clin.Chem.* 47(3): 418-25.
- Roitt,I.; Brostoff,J. and Male, D. (1998). *Immunology*. 3<sup>rd</sup>. Ed. Mosby, Philadelphia. PP: 221-27.
- Rosenthal,P. and Haight, M. (1990). Aminotransferase as a prognostic index in infants with liver disease. *Clin.Chem.* 36: 46-8.
- Rost, N.S.; Wolf, P.; Kase, C.; et al. (2001). Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: The Framingham study. *Stroke*, 32: 2575-79.
- Rothkrants-Kos, S.; Schmitz, M.; Bekers, O.; Menheere, P and van Diejen-Visser, M. (2002). High sensitivity C-reactive protein methods examined. *Clin.Chem.* 48(2): 359-62.
- Rubin, E and Farber, J. (1998). *Pathology*. 3<sup>rd</sup> Ed. Lippincott Williams & Wilkins Pp: 757-778.

- Ruddy, S. (2003). Introduction to Rheumatic disease. In: Dale, D.; Federman, D. Web. MD. Scientific American Medicine. Vol. 1. Web. MD. INC. USA. Pp: 1296.
- Saito, T.; Murakami, M.; Shimazaki, Y.; Oobayshi, K.; Matsummoto, S. and Koga, T. (2003). Association between alveolar bone loss and elevated serum C-reactive protein in Japanese. J. Periodontal, 74(12): 1741-46.
- Sallam, T.; Cuevas, L. and Tong, C. (2003). Increase in susceptibility of young adults to hepatitis B infection in the Republic of Yemen. Trans. Roy. Soc. Trop. Med. Hyg. 97: 302-4.
- Sampietro, T.; Bigazzi, F.; Dalpino, B.; Fusaro, S.; Greco, F.; Tuoni, M. and Bionda, A. (2002). Increased plasma C-reactive plasma in familial hypoalphalipoproteinemia, a proinflammatory condition?. Circulation, 105:11-4.
- Santolaya, M.E.; Alvarez, A.; Becker, A.; Cofre, J.; Enriquez,; et al. (2001). Prospective, multicenter evaluation of risk factor associated with invasive bacterial infection in children with cancer, neutropenia and fever. J.Clin.Oncol. 19(14): 3415-21.
- Santolaya, M.E.; Cofre, J. and Beresi, V. (1994). C-reactive protein: A valuable aid for the management of febrile children with cancer and neutropenia. Clin.Infect. Dis. 18:589-95.
- Saribas, S.; Kocazeybek, B.; Aslan, M.; Altun, S.; Seyhun, Y.; Oner, Y. and Memisoglu, N. (2004). Do procalcitonin and C-reactive protein levels have a place in the diagnosis and follow-up of *Helicobacter pylori* infection. J.Med.Microbiol. 53: 639-44.
- Seddon, J.; Gensler, G. Milton, R.; Klein, M. and Rifai, G. (2004). Association between C-reactive protein and age related macular degeneration. JAMA. 291: 704-10.
- Shaked, A.; Nunes, F.; Olthoff, K. and Lucey, M. (1997). Assessment of liver function: Pre and Peritransplant evaluation. Clin. Chem. 43: 1539-45.
- Shaya, G.H.; Al-Rawi, K.; Ali, S. and Selman, J. (2002). The diagnostic and prognostic value of C-reactive protein in patients with acute myocardial

- infarction into CCU- in Saddam General Hospital in Al-Ramadi city. Al-Anbar Med. J. 4: 57-63.
- Shine, B.; de Beer, F. and Pepys M.B. (1981). Solid phase radioimmunoassay for human C-reactive protein. Clin. Chem. Acta. 117: 123-23.
- Smith, S.J.; Bos, G.; Esseveld, M.; VanEijk, H. and Gerbrandy, J. (1977). Acute phase protein from the liver and enzymes from myocardial infarction; a quantitative relationship. Clin Chim. Acta. 81: 75-85.
- Stam, F.; van Guldener, C.; Schalkijk, C.; ter-Wee, P.; Donker, A. and Stehouwer, C. (2003). Impaired renal function is associated with markers of endothelial dysfunction and increased inflammatory activity. Nephrol. Dial. Transpl. 18(5): 892-98.
- Stearman, M. and Southgate, H. J. (1994). The use of cytokine and C-reactive Protein measurements in cerebrospinal fluid during acute infective meningitis. Ann. Clin. Biochem. 31: 2ss – 61.
- Tarkkinen, P.; Palenius, T. and Lovgren, T. (2002). Ultrarapid, ultrasensitive one-step kinetic immunoassay for C-reactive protein. In whole blood samples: measurement of the entire CRP concentration range with a single sample dilution. Clin. Chem. 48: 269-77.
- Teppo, A.M.; Tornroth, T.; Honkanen, E. and Gronhagen, (2003). Elevated serum C-reactive protein association with deterioration of renal function in transplant recipients. Clin. Nephrol. 60(4): 248-56.
- Tietz, NW, Rinker, D. Shaw, L.M. (1983). IFCC method for alkaline phosphatase. J. Clin. Chem. Clin. Biochem. 21: 731-48.
- Thomas, H. and Waters, J. (1998). Hepatitis B virus infection and immunity. In: Delves P. and Roitt, J. Encyclopedia of Immunology. Vol. 2. 2<sup>nd</sup>. Ed. Academic Press. PP 1075-78.
- Thomas, L. (1998). Clinical Laboratory Diagnostics: Use and assessment of clinical laboratory results. 1<sup>st</sup>. Ed. TH-Books.
- Thompson, D.; Miford, A. Whicher, J. (1992). The value of acute phase protein measurement in clinical practice. Ann. Clin. Biochem. 29: 123-31.

- Thompson, D. ; Pepys , M . B . ; and wood , S . P . ( 1999 ) . The physiological structure of human C- reactive protein and its complex with phosphocholine . *Structure* , 1 : 169 – 177 .
- Tolman,K. and Rej,R.(1999). Liver function. In: Burtis, C. and Ashwood, E. *Tiets Textbook of Clinical Chemistry*. Vol.2. 3<sup>rd</sup>.Ed. Saunders company. PP 1152-71.
- Verma, S.L.; Badiwala, M.; Weisel, R.; Fedak,P.; Dihillon, B. and Micle. (2002). Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. *Circulation*, 105: 1890-96.
- Verma, S.L.; Szmitko, P. and Yeh, E. (2004). C-reactive protein structure effects function. *Circulation*, 109:1914-17.
- Vigushin, D.M.; Pepys,M. and Howkins,P. (1993). Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. *J.Clin.Invest.* 91:1351-57.
- Volanakis, J.E. (1982). Complement activationby C-reactive protein complexes. *Ann.N.Y. Acad. Sci.* 389: 235-50.
- Voller, A.; Bartlett, A. and Bidwell, D.E. Enzyme immunoassays with special reference to EISA Techniques. *J. Clin. Pathol.* 31: 507-520.
- Wang, C.; Li, S.; Weisel, R.; Fedak, P.; Dumont, A.; et al. (2003). C-reactive protein upregulates angiotensin type 1 receptor in vascular smooth muscle. *Circulation*, 107: 1783-90.
- Wang, T.; Larson, M.; Levy,D.; Benjamin, E.; Kupka, M.; et al.( 2002). C-reactive protein is associated with subclinical epicardial coronary calcification in men and the Framingham heart study. *Circulation*, 106: 1189-91.
- Wasunna, A.; Whitelaw, A.; Gallimore, R.; Hawkins, P. and Pepys, M. (1990). C-reactive protein and bacterial infection in preterm infants. *Eurp. J.Pediatr.* 149: 424-27.



- Watanabe, A.; Kohno, A.; Niki, Y. and Saito, A. (2001). Comparison of chest X-ray finding and other parameters in acute exacerbation of chronic bronchitis in Japan and the West. *J.Infect. Chemother.* 7(1): 37-44.
- Wen, Y.;Duan, S.; Howard, C.; et al. (1990). The affinity of anti-HBc antibodies in acute and chronic hepatitis B infection. *Clin. Exp. Immunol.* 79: 83-86.
- Whicher, J.(1998). C-reactive protein. In: Thomas L. Clinical laboratory Diagnostic: Use and assessment of clinical laboratory results. 1<sup>st</sup>.Ed. TH-Books. PP 700-6.
- Whichner, J.; Ritchie, R.;Johnson,M.; et al.(1994). New international reference preparation for plasma proteins in human serum. *Clin.Chem.* 40:934-8.
- Wild,J. Grusby, M.;Schirmbeck, R. and Reimann,J. (1999). Priming MHC-I restricted cytotoxic T lymphocyte responses to exogenous hepatitis B surface antigen is CD4 T cell dependent. *J.Immunol.* 163: 1880-87.
- Wilkins, J.; Gallimore, J.; Moore, E. and Pepys,M.(1998). Rapid automated high sensitivity enzyme immunoassay of C-reactive protein. *Clin.Chem.* 44:1358-61.
- Willems,G.; vd Veen, F.; et al. (1985). Enzymatic assessment of myocardial necrosis after cardiac surgery: Differentiation from skeletal muscle damage, hemolysis, and liver injury. *Am.Heart J.* 109: 1243-52.
- Witt, J. and Trendelenburg, Chr. (1982). Joint study for the evaluation of reference values for clinical chemistry parameters in childhood. *J. Clin. Chem. Biochem.* 20: 235-42.
- Wu, H.P.; Chang, C. and Lin, C. (2003). Predictive inflammatory parameters n the diagnosis of acute appendicitis in children. *Acta.Pediatr. Taiwan,* 44(4): 227-31.
- Yamada, S.; Gotoh,T.; Nakashima, Y.; Kayaba,K.; et al. (2001). Distributionof serum C-reactive protein and its association with atherosclerotic risk factors in Japanese population. *AmJ.Epidemiol.*153: 1183-90.
- Yang, H.-L.; Lu, S.-N.; Liaw, Y.-F.; You,S.-L.; Sun, C.-A.; et al. (2002). Hepatitis Be antigen and the risk of hepatocellular carcinoma. *N.E.J. Med.* 347: 168-174.
- Young, B.; Gleeson, M. and Cripps, A. (1991). C-reactive protein: A critical review. *Pathology*, 23: 118-24.

- Zakrzewska, H.; Kozłowski, L. and Wojtukiewicz, M. (2003). Assessment of changes in levels of interleukin-6 and C-reactive protein in patients with breast tumor. *Pol. Merkuriusz. Lek.* 15: 115-7.
- Zilva, J.F. and Pannall, P. (1984). *Clinical chemistry in diagnosis and treatment*. 4<sup>th</sup>. Ed. Lloyd-Luke. PP.